Mitva Patel, MD, on the Use of Contrast-Enhanced Mammograms

News
Video

The expert in breast imaging spoke about the use of the technology, and why it is more effective than traditional mammograms.

Contrast-enhanced mammograms are more sensitive than traditional mammograms, as they are able to provide detail that typically requires an MRI.

In addition, the technology is much faster and more cost-effective than traditional mammograms. Though contrast-enhanced mammograms are not yet widely available, the technology is steadily improving breast cancer detection.

In an interview with CancerNetwork®, Mitva Patel, MD, a radiologist at The Ohio State University Comprehensive Cancer Center (OSUCCC) who specializes in breast imaging, discussed the use of contrast-enhanced mammograms and how the technology may advance breast imaging moving forward.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Recent Videos
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content
Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Tim Cortese
May 5th 2025
Article

Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors

Caroline Seymour
April 29th 2025
Article

A phase 2 study found a complete clinical response of 82% with neoadjuvant dostarlimab in dMMR solid tumors.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

Tim Cortese
April 24th 2025
Article

The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-G12D mutation.